Combination therapy in advanced urothelial cancer: the role of PARP, HER-2 and mTOR inhibitors

ANTONIO LOPEZ BELTRAN2026-01-292026-01-29202010.1080/14737140.2020.18073342-s2.0-85089506575https://www.scopus.com/inward/record.uri?eid=2-s2.https://ucocris.uco.es/handle/123456789/32153OncologyPharmacology (medical)OncologyPharmacology (medical)Combination therapy in advanced urothelial cancer: the role of PARP, HER-2 and mTOR inhibitorsreview article